The Prognostic Nutritional Index (PNI) and systemic oxidative stress (SOS) score are independently associated with poorer ...

Allogeneic hematopoietic cell transplantation (allo-HCT) is feasible in older patients with myelodysplastic syndrome (MDS), ...

AMESBURY – Cider Hill Farm is preparing to host a number of blood drives in the coming months, inspired by the story of their ...

When 15-month-old Nora received her diagnosis, no one could have predicted the impact it would have on her sister Kayla.

María Díez Campelo, MD, PhD, concludes by highlighting imetelstat’s real-world quality of life benefits for patients with ...

An expert discusses how real-world evidence and patient-reported outcomes support luspatercept’s clinical benefits, while ...

An expert discusses how optimal sequencing of therapies remains unclear in lower-risk MDS, with emerging combination ...

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

It took a misplaced elbow, a quirk of Los Angeles geography and some whistling from his wife to produce one of television’s ...